Davis Polk advised the joint book-running managers and representatives of the several underwriters on an SEC-registered offering by Celgene Corporation of $500 million aggregate…
Davis Polk advised the joint book-running managers in connection with the $133.7 million initial public offering of common stock of Solid Biosciences Inc. The common stock is listed on the…
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 8,152,986 shares of common stock of…
Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant to the…
Davis Polk advised the sole book-running manager in connection with the $50 million follow-on offering of 1,970,000 shares of common stock of Editas Medicine, Inc. The common…
Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $750 million aggregate principal amount of 2.750% senior notes due 2023, $1…
Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230 million of its ordinary shares in the form of American Depositary…
Davis Polk advised the underwriters in connection with an initial public offering of 7,500,000 shares of common stock of Deciphera Pharmaceuticals, Inc., at $17.00 per share, for total…
Davis Polk is advising ABB on its approximately $2.6 billion acquisition of GE Industrial Solutions, General Electric Company’s global electrification solutions business. The transaction,…
Davis Polk advised the joint book-running managers and representatives of the underwriters on the $172.5 million initial public offering by Zai Lab Limited of 9,583,333 American…